Benefits and Safety of Long-Term Fenofibrate Therapy in People With Type 2 Diabetes and Renal Impairment
Open accessThe DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Diabetic patients with moderate renal impairment (estimated glomerular filtration rate [eGFR] 30–59 mL/min/1.73 m2) are at particular cardiovascular risk. Fenofibrate’s safety in these patients is an issue because it may elevate plasma creatinine. Furthermore, guidelines regarding fenofibrate dosing in renal impairment vary internationally. We investigated fenofibrate’s effects on cardiovascular and end-stage renal disease (ESRD) events, according to eGFR, in the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study. RESEARCH DESIGN AND METHODS: Type 2 diabetic patients (aged 50–75 years) with eGFR ≥30 mL/min/1.73 m2 were randomly allocated to a fixed dose of fenofibrate (200 mg daily) (n = 4,895) or placebo (n = 4,900) for 5 years. Baseline renal function (Modification of Diet in Renal Disease equation) was grouped by eGFR (30–59, 60–89, and ≥90 mL/min/1.73 m2). The prespecified outcome was total cardiovascular events (composite of cardiovascular death, myocardial infarction, stroke, and coronary/carotid revascularization). Serious adverse events and instances of ESRD (plasma creatinine >400 μmol/L, dialysis, renal transplant, or renal death) were recorded. Analysis was by intention to treat. RESULTS: Overall, fenofibrate reduced total cardiovascular events, compared with placebo (hazard ratio 0.89 [95% CI 0.80–0.99]; P = 0.035). This benefit was not statistically different across eGFR groupings (P = 0.2 for interaction) (eGFR 30–59 mL/min/1.73 m2: 0.68 [0.47–0.97], P = 0.035; eGFR ≥90 mL/min/1.73 m2: 0.85 [0.70–1.02], P = 0.08). ESRD rates were similar between treatment arms, without adverse safety signals of fenofibrate use in renal impairment. CONCLUSIONS: Patients with type 2 diabetes and moderate renal impairment benefit from long-term fenofibrate, without excess drug-related safety concerns compared with those with no or mild renal impairment. Fenofibrate treatment should not be contraindicated in moderate renal impairment, suggesting that current guidelines may be too restrictive.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This is a known effect of PPAR-α agonists.[27][28][29]”
From A Placebo-Controlled Trial of Bezafibrate in Primary Biliary Cholangitis (2018) · cites this paper as [28]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Turner, R. C., Fox, C., Matthews, McElroy, H. H., Cull, C. A., Holman, R. R., Neil, P., Hadden, D. R., Wright, D., Manley, E., et al. (1998) · The Lancet · Cited by 8,419
Brenner, B. M., Cooper, M. E., de Zeeuw, D., Keane, W. F., Mitch, W. E., Parving, H.-H., Remuzzi, G., Snapinn, S. M., Zhang, Z., & Shahinfar, S. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011161 · Cited by 7,493
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802987 · Cited by 7,397
Stearne, M. R., Palmer, S. L., Hammersley, M. S., Franklin, S. L., Spivey, R. S., Lévy, J., Tidy, C. R., Bell, N. J., Steemson, J., Barrow, B. A., et al. (1998) · UCL Discovery (University College London) · Cited by 6,090
Effect of a multifactorial intervention on mortality in type 2 diabetes
Gæde, P., Lund-Andersen, H., Parving, H.-H., & Pedersen, O. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0706245 · Cited by 3,465 · cited 1×
“Unfortunately, the implementation of established preventive treatment recommendations remains incomplete (24), and even with intensive multifactorial risk reduction, the CVD complication rate in type 2 diabetic patients remains unacceptably high (25).”
Background(2005) · The Lancet · doi:10.1016/s0140-6736(05)67667-2 · Cited by 3,284 · cited 4×
“The rise in plasma creatinine in response to fenofibrate is well documented, but this does not reflect true renal injury or an actual fall in glomerular filtration rate (GFR) (4,7,10).”
BackgroundInfluentialEffects of Combination Lipid Therapy in Type 2 Diabetes Mellitus
(2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001282 · Cited by 2,837
Research works printed but not linked: 1
- Laboratoires Fournier, 2004, Fenofibrate Investigator’s Brochure
Cited by
Ratziu, V., Harrison, S. A., Francque, S., Bedossa, P., Lehert, P., Serfaty, L., Romero-Gomez, M., Boursier, J., Abdelmalek, M., Caldwell, S., et al. (2016) · Gastroenterology · doi:10.1053/j.gastro.2016.01.038 · Cited by 1,035
National Lipid Association Recommendations for Patient-Centered Management of Dyslipidemia: Part 2
Jacobson, T. A., Maki, K. C., Orringer, C. E., Jones, P. H., Kris-Etherton, P., Sikand, G., La Forge, R., Daniels, S. R., Wilson, D. P., Morris, P. B., et al. (2015) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2015.09.002 · Cited by 784
“Based on the limited available outcomes data, the main clinical situation in which fenofibrate or fenofibric acid could be considered as a statin combination therapy would be in type 2 diabetes patients with a non-HDL-C not at goal, who also have retinopathy and/or microalbuminuria, and do not have stage 3B or worse C…”
MethodA Placebo-Controlled Trial of Bezafibrate in Primary Biliary Cholangitis
Corpechot, C., Chazouillères, O., Rousseau, A., Le Gruyer, A., Habersetzer, F., Mathurin, P., Goria, O., Potier, P., Minello, A., Silvain, C., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1714519 · Cited by 642
Signaling pathways of chronic kidney diseases, implications for therapeutics
Yuan, Q., Tang, B., & Zhang, C. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01036-5 · Cited by 453
Ghonem, N. S., Assis, D. N., & Boyer, J. L. (2015) · Hepatology · doi:10.1002/hep.27744 · Cited by 317
The next generation of therapeutics for chronic kidney disease
Breyer, M. D., & Susztak, K. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.67 · Cited by 272
de Vries, E., Bolier, R., Goet, J., Parés, A., Verbeek, J., de Vree, M., Drenth, J., van Erpecum, K., van Nieuwkerk, K., van der Heide, F., et al. (2021) · Gastroenterology · doi:10.1053/j.gastro.2020.10.001 · Cited by 224
Jones, D., Boudes, P. F., Swain, M. G., Bowlus, C. L., Galambos, M. R., Bacon, B. R., Doerffel, Y., Gitlin, N., Gordon, S. C., Odin, J. A., et al. (2017) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(17)30246-7 · Cited by 191
Effects of Fibrates in Kidney Disease
Jun, M., Zhu, B., Tonelli, M., Jardine, M. J., Patel, A., Neal, B., Liyanage, T., Keech, A., Cass, A., & Perkovic, V. (2012) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.07.049 · Cited by 189
Self-citationResidual macrovascular risk in 2013: what have we learned?
(R3i), F. T. R. R. R. I., Fruchart, J.-C., Davignon, J., Hermans, M. P., Al-Rubeaan, K., Amarenco, P., Assmann, G., Barter, P., Betteridge, J., Bruckert, E., et al. (2014) · Cardiovascular Diabetology · doi:10.1186/1475-2840-13-26 · Cited by 172
Therapeutic approaches to diabetic nephropathy—beyond the RAS
Fernandez-Fernandez, B., Ortiz, A., Gomez-Guerrero, C., & Egido, J. (2014) · Nature Reviews Nephrology · doi:10.1038/nrneph.2014.74 · Cited by 170
The Evolving Understanding of the Contribution of Lipid Metabolism to Diabetic Kidney Disease
Stadler, K., Goldberg, I. J., & Susztak, K. (2015) · Current Diabetes Reports · doi:10.1007/s11892-015-0611-8 · Cited by 165
Primary biliary cholangitis: Epidemiology, prognosis, and treatment
Trivella, J., John, B. V., & Levy, C. (2023) · Hepatology Communications · doi:10.1097/hc9.0000000000000179 · Cited by 159
“derive from renal hemodynamic changes and/or an increased creatinine release by muscle but does not reflect renal toxicity.[111,112] Liver biochemistries and renal function should be monitored periodically in PBC patients on fibrates, and its use should be avoided in those with decompensated liver disease.”
BackgroundReiner, Ž. (2013) · Nutrition, Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2013.05.002 · Cited by 147
Guideline Development Group., Bilo, H. J. G., Coentrão, L., Couchoud, C., Covic, A. C., SUTTER, J. D., Drechsler, C., Gnudi, L., Goldsmith, D. J. A., Heaf, J. G., et al. (2015) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfv100 · Cited by 189
Loss of endothelial glucocorticoid receptor accelerates diabetic nephropathy
Srivastava, S. P., Zhou, H., Setia, O., Liu, B., Kanasaki, K., Koya, D., Dardik, A., Fernandez-Hernando, C. F., & Goodwin, J. E. (2021) · Nature Communications · doi:10.1038/s41467-021-22617-y · Cited by 152
Noonan, J. E., Jenkins, A. J., Ma, J.-X., Keech, A. C., Wang, J. J., & Lamoureux, E. L. (2013) · Diabetes · doi:10.2337/db13-0800 · Cited by 120
Self-citationClinical Challenges in Diagnosis and Management of Diabetic Kidney Disease
Stanton, R. C. (2014) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2013.10.050 · Cited by 115
“Fenofibrate increased creatinine levels initially, but this was not maintained, and 2 more recent studies suggest that fenofibrate likely is safe to use in patients with moderate kidney disease.(129,130) However, more studies clearly are needed to determine whether treatment of cholesterol and/or triglyceride levels w…”
Fenofibrate – A Potential Systemic Treatment for Diabetic Retinopathy?
Wong, T. Y., Simó, R., & Mitchell, P. L. R. (2012) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2012.03.013 · Cited by 107
KONES, R. J. (2013) · Vascular Health and Risk Management · doi:10.2147/vhrm.s37119 · Cited by 103
Hegade, V. S., Khanna, A., Walker, L. J., Wong, L.-L., Dyson, J. K., & Jones, D. E. J. (2016) · Digestive Diseases and Sciences · doi:10.1007/s10620-016-4250-y · Cited by 86
Peroxisome Proliferator-Activated Receptor α in Lipid Metabolism and Atherosclerosis
Yu, X., Zheng, X., & Tang, C. (2015) · Advances in clinical chemistry · doi:10.1016/bs.acc.2015.06.005 · Cited by 71
Lipid mediators in diabetic nephropathy
Srivastava, S. P., Shi, S., Koya, D., & Kanasaki, K. (2014) · Fibrogenesis & Tissue Repair · doi:10.1186/1755-1536-7-12 · Cited by 67
“At the same time, clinical studies have shown that in patients with DN, lipid-lowering drugs could be associated with a reduction in the proteinuria but not with a remarkable improvement in the kidney outcome [3,4].”
BackgroundHow to control residual cardiovascular risk despite statin treatment: Focusing on HDL–cholesterol
Lim, S. K., Park, Y. M., Sakuma, I., & Koh, K. K. (2012) · International Journal of Cardiology · doi:10.1016/j.ijcard.2012.03.127 · Cited by 69
Kalil, R. S., Wang, J., de Boer, I. H., Mathew, R. O., Ix, J. H., Asif, A., Shi, X., & Boden, W. E. (2015) · Kidney International · doi:10.1038/ki.2014.383 · Cited by 68
“shown to be cardio protective in non-dialytic CKD patients (16, 17).”
BackgroundFenofibrate and the kidney: an overview
Kostapanos, M. S., Florentin, M., & Elisaf, M. S. (2013) · European Journal of Clinical Investigation · doi:10.1111/eci.12068 · Cited by 65
Monteillet, L., Gjorgjieva, M., Silva, M., Verzieux, V., Imikirene, L., Duchampt, A., Guillou, H., Mithieux, G., & Rajas, F. (2018) · Molecular Metabolism · doi:10.1016/j.molmet.2018.07.006 · Cited by 70
Regulation of pericyte metabolic reprogramming restricts the AKI to CKD transition
Xu, C., Hong, Q., Zhuang, K., Ren, X., Cui, S., Dong, Z., Wang, Q., Bai, X., & Chen, X. (2023) · Metabolism · doi:10.1016/j.metabol.2023.155592 · Cited by 70
Nevens, F., Trauner, M., & Manns, M. P. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2022.10.007 · Cited by 55
Cicero, A. F. G., Pontremoli, R., Fogacci, F., Viazzi, F. C., & Borghi, C. (2020) · Drug Safety · doi:10.1007/s40264-020-00931-6 · Cited by 55
Hadjivasilis, A., Kouis, P., Kousios, A., & Panayiotou, A. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11030768 · Cited by 46
“Fenofibrates were found to be effective and safe in the FIELD study, even for patients with reduced eGFR [49].”
BackgroundMusso, G., De Michieli, F., Bongiovanni, D., Parente, R., Framarin, L., Leone, N., Berrutti, M., Gambino, R., Cassader, M., Cohney, S., et al. (2017) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2016.08.002 · Cited by 38
“In diabetic nephropathy, fibrates decreased albuminuria and slowed eGFR decrease independently of their lipid-lowering properties, but the overall effect was small and their interference with creatinine excretion can increase serum creatinine levels.(28) The novel, more potent, and selective PPAR-a, PPAR-d, and dual P…”
BackgroundLipid abnormality in diabetic kidney disease and potential treatment advancements
Tu, Q. M., Jin, H. M., & Yang, X. H. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1503711 · Cited by 53
Amatruda, M., Gembillo, G., Giuffrida, A. E., Santoro, D., & Conti, G. (2021) · Medicina · doi:10.3390/medicina57090868 · Cited by 42
GFT505 for the treatment of nonalcoholic steatohepatitis and type 2 diabetes
Cariou, B., & Staels, B. (2014) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2014.954034 · Cited by 36
“Although PPARa agonism often results in a moderate increase in plasma creatinine levels, certain data sustain the hypothesis that fibrates do not impair kidney function [45] and could even slow the progression of diabetic nephropathy [46].”
BackgroundTherapeutic Effects of PPARαon Neuronal Death and Microvascular Impairment
Pearsall, E., & Ma, J. (2015) · PPAR Research · doi:10.1155/2015/595426 · Cited by 34
New treatments/targets for primary biliary cholangitis
Corpechot, C., Poupon, R. Y., & Chazouillères, O. (2019) · JHEP Reports · doi:10.1016/j.jhepr.2019.05.005 · Cited by 32
“Bezafibratewas associatedwith a significant increase in serum creatinine level of 5% at 24 months, a well-known class effect of fibrates with no long-term impact on renal function.(55) Patients with features of portal hypertension or highALP levels at baselinewere less likely to respond to bezafibrate and tomeet the p…”
BackgroundReversal of obesity-induced hypertriglyceridemia by (R)-α-lipoic acid in ZDF (fa/fa) rats
Yi, X., Pashaj, A., Xia, M., & Moreau, R. F. (2013) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2013.08.063 · Cited by 31
Lipid-lowering agents for concurrent cardiovascular and chronic kidney disease
Katsiki, N., Mikhailidis, D. P., & Banach, M. (2019) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2019.1649394 · Cited by 28
Lipid Disorders in Uremia and Dialysis
Bakris, G. L. (2012) · Contributions to nephrology · doi:10.1159/000337821 · Cited by 24
Fenofibrate-induced renal dysfunction, yes or no?
Nematbakhsh, M., Emami, F., Hariri, A., & Matinfar, M. (2020) · Journal of Research in Medical Sciences · doi:10.4103/jrms.jrms_772_19 · Cited by 25
Ruilope, L. M., Hanefeld, M., Lincoff, A. M., Viberti, G. C., Reigner, S. M., Mudie, N. Y., Kirk, D. A. W., Malmberg, K., & Herz, M. (2014) · BMC Nephrology · doi:10.1186/1471-2369-15-180 · Cited by 27
Pontremoli, R., Bellizzi, V., Bianchi, S., Bigazzi, R., Cernaro, V., Vecchio, L. D., Nicola, L. D., Leoncini, G., Mallamaci, F., Zoccali, C., et al. (2020) · Journal of Nephrology · doi:10.1007/s40620-020-00707-2 · Cited by 30
Safety considerations with fenofibrate/simvastatin combination
Filippatos, T. D., & Elisaf, M. (2015) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2015.1056778 · Cited by 24
“Indeed, it was shown that the cardiovascular risk reduction in patients with chronic kidney disease was similar with the entire cohort [105].”
ResultStatins and Cardiovascular Disease Outcomes in Chronic Kidney Disease: Reaffirmation vs. Repudiation
Obialo, C. I., Ofili, E., & Norris, K. C. (2018) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph15122733 · Cited by 24
Metabolic Syndrome, Kidney-Related Adiposity, and Kidney Microcirculation: Unraveling the Damage
Jang, K. W., Hur, J., Lee, D. W., & Kim, S. R. (2024) · Biomedicines · doi:10.3390/biomedicines12122706 · Cited by 28
Yen, C., Fan, P., Lin, M., Lee, C., Tu, K., Chen, C., Hsiao, C.-C., Hsu, H., Tian, Y., & Chang, C. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab137 · Cited by 20
Mark, P. B., Winocour, P. H., & Day, C. (2017) · British Journal of Diabetes · doi:10.15277/bjd.2017.125 · Cited by 18
Enfermedad renal crónica y dislipidemia
Pascual, V., Serrano, A., Pedro‐Botet, J., Ascaso, J. F., Barrios, V., Millán, J., Pintó, X., & Cases, A. (2016) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/j.arteri.2016.07.004 · Cited by 31
Taylor, K., McLellan, J., Verbakel, J. Y. J., Aronson, J. K., Lasserson, D. S., Pidduck, N., Roberts, N. W., Fleming, S., O’Callaghan, C. A., Bankhead, C. R., et al. (2019) · BMJ Open · doi:10.1136/bmjopen-2019-030596 · Cited by 18
Czupryniak, L., Joshi, S., Gogtay, J. A., & Lopez, M. (2016) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2016.1195811 · Cited by 19
Makówka, A., Dryja, P., Chwatko, G., Bald, E., & Nowicki, M. P. (2012) · Lipids in Health and Disease · doi:10.1186/1476-511x-11-47 · Cited by 18
Peroxisome proliferator-activated receptor agonists in a battle against the aging kidney
Speeckaert, M. M., Vanfraechem, C., Speeckaert, R., & Delanghe, J. (2014) · Ageing Research Reviews · doi:10.1016/j.arr.2014.01.006 · Cited by 19
“Recently the safety of long-term fenofibrate therapy in people with type 2 diabetes and renal impairment was demonstrated (Ting et al., 2012).”
BackgroundPais, R., Cariou, B., Noureddin, M., Francque, S., Schattenberg, J. M., Abdelmalek, M. F., Lalazar, G., Varma, S., Dietrich, J., Miller, V., et al. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.03.014 · Cited by 15
Papademetriou, V., Lovato, L., Tsioufis, C. P., Cushman, W. C., Applegate, W. B., Mottle, A., Punthakee, Z., Nylén, E., Doumas, M. N., & for the ACCORD Study Group (2016) · American Journal of Nephrology · doi:10.1159/000453626 · Cited by 16
Triglyceride Treatment in the Age of Cholesterol Reduction
Agrawal, N., Corradi, P. F., Gumaste, N., & Goldberg, I. J. (2016) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2016.08.003 · Cited by 15
Atkinson‐Briggs, S., Jenkins, A. J., Ryan, C. J., & Brazionis, L. (2022) · Journal of Advanced Nursing · doi:10.1111/jan.15163 · Cited by 16
Self-citationAlbarrán, O. G., Morales, C., Pérez-Maraver, M., Aparicio-Sánchez, J. J., & Simó, R. (2022) · Diabetes Therapy · doi:10.1007/s13300-022-01276-2 · Cited by 16
Nemcsik, J., Cseprekál, O., Egresits, J., Kielstein, J. T., Kümpers, P., Lukasz, A. H., Tabák, Á. G., Marton, A., Németh, Z., Járai, Z., et al. (2017) · Journal of Hypertension · doi:10.1097/hjh.0000000000001256 · Cited by 14
“Although fibrates can increase creatinin, the safety of their use above GFR 30 ml/min was confirmed by the huge, randomized FIELD study [35].”
BackgroundTriglycerides Revisited to the Serial
Viecili, P. R. N., da Silva, B., Hirsch, G. E., Porto, F. G., Parisi, M. M., Castanho, A. R., Wender, M., & Klafke, J. Z. (2017) · Advances in clinical chemistry · doi:10.1016/bs.acc.2016.11.001 · Cited by 21
How PPAR-alpha mediated inflammation may affect the pathophysiology of chronic kidney disease
Masenga, S. K., Desta, S., Hatcher, M. D., Kirabo, A., & Lee, D. L. (2024) · Current Research in Physiology · doi:10.1016/j.crphys.2024.100133 · Cited by 19
Dislipidemia aterogénica y riesgo residual. Estado de la cuestión en 2014
Núñez-Cortés, J. M., Pedro‐Botet, J., & Pintó, X. (2014) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/j.arteri.2014.09.004 · Cited by 20
The case for intraocular delivery of PPAR agonists in the treatment of diabetic retinopathy
Treacy, M. P., & Hurst, T. P. (2012) · BMC Ophthalmology · doi:10.1186/1471-2415-12-46 · Cited by 11
Chronic kidney disease and dyslipidaemia
Pascual, V., Serrano, A., Pedro‐Botet, J., Ascaso, J. F., Barrios, V., Millán, J., Pintó, X., & Cases, A. (2017) · Clínica e Investigación en Arteriosclerosis (English Edition) · doi:10.1016/j.artere.2016.04.001 · Cited by 13
Summarizing the FIELD study: lessons from a ‘negative' trial
Tsimihodimos, V., Mikhailidis, D. P., & Elisaf, M. (2013) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2013.850075 · Cited by 10
“73 m(2) and CVD and all-cause death were more than six- and fourfold higher, respectively [41].”
BackgroundInfluentialWeinstein, D. L., Williams, L. A., Carlson, D. M., Kelly, M. T., Burns, K. M., Setze, C. M., Lele, A., & Stolzenbach, J. C. (2013) · Clinical Therapeutics · doi:10.1016/j.clinthera.2013.06.013 · Cited by 13
Not enough known about fenofibrate’s kidney effects in people with Type 2 diabetes
Jenkins, A. J., O'Connell, R. L., Januszewski, A. S., Webster, A. C., Davis, T. M. E., Jardine, M., Scott, R. S., Taskinen, M., & KEECH, A. C. (2024) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2024.111612 · Cited by 11
Self-citationOng, K. L., Wu, L., Januszewski, A. S., O'Connell, R. L., Xu, A., Scott, R. S., SULLIVAN, D. R., Rye, K., Li, H., Ronald, C. W., et al. (2021) · Diabetes and Vascular Disease Research · doi:10.1177/14791641211032547 · Cited by 9
Self-citationLiao, G., Wang, X., Li, Y., Chen, X., Huang, K., Bai, L., Ye, Y., & Peng, Y. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics15010006 · Cited by 11
“Fibrates with/without statins could effectively further improve lipid parameters (especially TG and HDL-c) and reduce total cardiovascular events [15,33,47,67] among CKD persons.”
Uemura, T., Nishimoto, M., Eriguchi, M., Tamaki, H., Tasaki, H., Furuyama, R., Fukata, F., Kosugi, T., Morimoto, K., Matsui, M., et al. (2023) · Hypertension Research · doi:10.1038/s41440-023-01197-y · Cited by 10
Cardiovascular Disease in Japanese Patients with Type 2 Diabetes Mellitus
Fujihara, K., & Sone, H. (2018) · Annals of Vascular Diseases · doi:10.3400/avd.ra.17-00109 · Cited by 10
Lipid-Lowering Therapy in CKD: Should We Use It and in Which Patients
Kaysen, G. A. (2017) · Blood Purification · doi:10.1159/000452727 · Cited by 8
AbdelMagid, A. M., Abbassi, M., Iskander, E. E. M., Mohamady, O., & Farid, S. F. (2017) · Journal of Comparative Effectiveness Research · doi:10.2217/cer-2016-0076 · Cited by 11
Tsai, M., Chen, M., Huang, Y.-C., Liou, H., & Fang, Y. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.804000 · Cited by 7
Harmer, J. A., KEECH, A. C., Veillard, A.-S., Skilton, M. R., Watts, G. F., & Celermajer, D. S. (2018) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2018.05.006 · Cited by 7
Self-citationToth, P. P., & Banach, M. (2025) · Archives of Medical Science · doi:10.5114/aoms/216960 · Cited by 9
Ho, W.-Y., Yen, C., Lee, C., Tu, Y., Chen, C., Hsiao, C.-C., Chu, P., Hsu, H., Tian, Y.-C., & Chang, C. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.907539 · Cited by 7
Fenofibrate and renal disease: clinical effects in diabetes
Ting, R.-D., & KEECH, A. C. (2013) · Clinical Lipidology · doi:10.2217/clp.13.69 · Cited by 6
Self-citationYen, C., Fan, P., Lee, C., Chen, J., Chen, C., Tu, Y., Chu, P., Hsiao, C.-C., Chen, Y., & Chang, C. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1333553 · Cited by 6
Management of Diabetes Mellitus
Jenkins, A. J., SCOTT, E. S., Fulcher, J., Kilov, G., & Januszewski, A. S. (2018) · Contemporary cardiology · doi:10.1007/978-3-319-97622-8_7 · Cited by 6
Self-citationRole of Dyslipidemia in Patients With Chronic Kidney Disease
Marino, A., & Tannock, L. R. (2013) · Postgraduate Medicine · doi:10.3810/pgm.2013.07.2676 · Cited by 6
Streja, E., Streja, D. A., Soohoo, M., Kleine, C., Hsiung, J., Park, C., & Moradi, H. (2018) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2018.05.007 · Cited by 5
(2013) · Kidney International Supplements · doi:10.1038/kisup.2013.42 · Cited by 5
Chapter 5: Triglyceride-lowering treatment in adults
(2013) · Kidney International Supplements · doi:10.1038/kisup.2013.37 · Cited by 6
Lipid Abnormalities in Hemodialysis Patients
Ulusoy, Ş., & Ozk, G. (2013) · InTech eBooks · doi:10.5772/52925 · Cited by 5
“Patients with a GFR above 30 were included in that study, however (Ting et al., 2012).”
BackgroundMa, L.-Y., Fan, P., Chen, C., Tu, Y., Hsiao, C.-C., Yen, C., & Chang, C. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm13010168 · Cited by 6
Should we use fibrates in patients with diabetes and mild CKD?
Lewis, D., & Wanner, C. (2012) · Nature Reviews Nephrology · doi:10.1038/nrneph.2012.37 · Cited by 5
Darestani, S. G., Kurano, M., Shinnakasu, A., Yamamoto, K., Dochi, Y., Uemura, K., Ikeda, Y., Arimura, A., Arimura, H., Kikuchi, A., et al. (2019) · Diabetology International · doi:10.1007/s13340-019-00394-w · Cited by 3
Rodríguez, Á. D., Cumplido, A. S., Núñez-Cortés, J. M., de Miguel, M. R., & Peña, M. L. O. (2017) · Clínica e Investigación en Arteriosclerosis (English Edition) · doi:10.1016/j.artere.2017.07.004 · Cited by 3
Lipid-lowering agents in chronic kidney disease: do fibrates have a role?
Huang, Y., & Hu, Y. (2013) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2013.15-c1 · Cited by 3
Ishibashi, S., Arai, H., Yokote, K., Araki, E., Watanabe, M., Nakanishi, M., Makinose, Y., Suganami, H., Kurihara, Y., & Yamashita, S. (2024) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.64887 · Cited by 3
Dyslipidemia aterogenna w codziennej praktyce — interdyscyplinarny konsensus polskich ekspertów
Szymański, F. M., Filipiak, K. J., Wożakowska−Kapłon, B., Szaflik, J. P., Dzida, G. J., Kurkowska‐Jastrzębska, I., Narkiewicz, K., Łazicka-Gałecka, M., Gil, R. J., & Gumprecht, J. (2017) · Folia Cardiologica · doi:10.5603/fc.a2016.0106 · Cited by 4
Rodríguez, Á. D., Cumplido, A. S., Núñez-Cortés, J. M., de Miguel, M. R., & Peña, M. L. O. (2017) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/j.arteri.2017.04.003 · Cited by 3
Fenofibrate: a guide to its use in dyslipidaemia
Keating, G. M., & McKeage, K. (2012) · Drugs & Therapy Perspectives · doi:10.2165/11608570-000000000-00000 · Cited by 1
Matsuoka‐Uchiyama, N., Uchida, H. A., Asakawa, T., Sakurabu, Y., Katayama, K., Okamoto, S., Onishi, Y., Tanaka, K., Takeuchi, H., Takemoto, R., et al. (2025) · Clinical and Experimental Nephrology · doi:10.1007/s10157-025-02640-9 · Cited by 1
Repurposing Fenofibrate for Early Diabetic Retinopathy: A Systemic and Disease-Modifying Approach
Alfaleh, A. S., Al-Kuraishy, H. M., Alruwaili, M., Eliwa, D., & Batiha, G. E. (2026) · Seminars in Ophthalmology · doi:10.1080/08820538.2026.2673068 · Cited by 1
“109 Liver enzyme elevations are common, and baseline and periodic ALT/AST monitoring is recommended; fenofibrate also increases cholesterol excretion into bile, potentially increasing risk of cholelithiasis.”
Yi, X. (2013) · Lincoln (University of Nebraska) · Cited by 1
Rajas, F., & Mithieux, G. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-849886-6.00021-5 · Cited by 2
Lipoprotein Glycation in Diabetes Mellitus
Jenkins, A. J., Klein, R. L., Semler, A. J., & Januszewski, A. S. (2023) · Contemporary diabetes · doi:10.1007/978-3-031-26681-2_11 · Cited by 1
Self-citationNajafipour, F., Najafipour, M., Zareizadeh, M., & Khokhi, M. (2018) · Journal of Advanced Pharmaceutical Technology amp Research · doi:10.4103/japtr.japtr_314_18 · Cited by 1
Metadata
- Authors
- Ting, R.-D., Keech, A. C., Drury, P. L., Donoghoe, M. W., Hedley, J., Jenkins, A. J., Davis, T. M. E., Lehto, S., Celermajer, D., Simes, R. J., Rajamani, K., Stanton, K., & on behalf of the FIELD Study Investigators
- Affiliations
- The University of Sydney (AU)
- Auckland Diabetes Centre, Auckland, New Zealand
- Department of Internal Medicine, Wairau Hospital, Blenheim, New Zealand
- The University of Western Australia (AU)
- Kuopio University Hospital (FI)
- Royal Prince Alfred Hospital (AU)
- Royal Perth Hospital (AU)
- Corresponding author
- Ting, Ru-Dee
- Keech, Anthony C.
- ORCID
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2012-01-16
- Volume
- 35
- Issue
- 2
- Pages
- 218-225
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- PMC
- PMC3263870
- OpenAlex
- W2044493153
- Cited by
- 119
- References
- 36
- Citations by year
- 2026: 6 · 2025: 4 · 2024: 5 · 2023: 8 · 2022: 9 · 2021: 4 · 2020: 5 · 2019: 5 · 2018: 8 · 2017: 10 · 2016: 8 · 2015: 10 · 2014: 12 · 2013: 16 · 2012: 8
- FWCI
- 8.91
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Diabetes Care (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Minerva Access (University of Melbourne) (submittedVersion, cc-by-nc-nd)
- UWA Profiles and Research Repository (UWA) (submittedVersion, other-oa)
- Funders
- European Society of Cardiology
- Cardiac Society of Australia and New Zealand
- Medical Research Council
- National Health and Medical Research Council
- Topics
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- fenofibrate, type 2 diabetes, renal dysfunction, estimated glomerular filtration rate, cardiovascular events, end-stage renal disease, serum creatinine, drug safety, lipid-lowering therapy, fieldwork, cardiovascular risk, renal dose adjustment, myocardial infarction, stroke, coronary revascularization, renal death, dialysis, kidney transplantation, cardiovascular mortality, serious adverse events
- MeSH terms
- Aged, Hypolipidemic Agents, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Female, Glomerular Filtration Rate, Humans, Kidney Failure, Chronic, Male, Middle Aged, Fenofibrate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.